© 2005 Foundation for Promotion of Cancer Research
Standard Thoracic Radiotherapy With or Without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced Non-small Cell Lung Cancer: a Phase III Trial of the Japan Clinical Oncology Group (JCOG9812)
1 National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, 2 National Cancer Center Hospital, Tokyo, 3 Kanagawa Cancer Center, Yokohama, 4 Yokohama Municipal Citizen's Hospital, Yokohama, 5 Niigata Cancer Center Hospital, Niigata, 6 Aichi Cancer Center, Nagoya, 7 Kumamoto Regional General Hospital, Kumamoto, 8 National Cancer Center Hospital East, Kashiwa, Chiba and 9 The Statistics and Cancer Control Division, National Cancer Center, Tokyo, Japan
For reprints and all correspondence: Shinji Atagi, National Hospital Organization Kinki-Chuo Chest Medical Center, 1180 Nagasone, Sakai, Osaka, 591-8555, Japan. E-mail: s-atagi{at}kch.hosp.go.jp
Received October 20, 2004; accepted February 14, 2005
Background: The purpose of this study was to evaluate whether radiotherapy with carboplatin would result in longer survival than radiotherapy alone in elderly patients with unresectable stage III non-small cell lung cancer (NSCLC).
Methods: Eligible patients were 71 years of age or older with unresectable stage III NSCLC. Patients were randomly assigned to the radiotherapy alone (RT) arm, irradiation with 60 Gy; or the chemoradiotherapy (CRT) arm, the same radiotherapy and additional concurrent use of carboplatin 30 mg/m2 per fraction up to the first 20 fractions.
Results: This study was terminated early when 46 patients were registered from November 1999 to February 2001. Four patients (one in the RT arm, three in the CRT arm) were considered to have died due to treatment-related causes. The JCOG Radiotherapy Committee assessed these treatment-related deaths (TRDs) and the compliance with radiotherapy in this trial. They found that 60% of the cases corresponded to protocol deviation and 7% were protocol violation in dose constraint to the normal lung, two of whom died due to radiation pneumonitis. As to the effectiveness for the 46 patients enrolled, the median survival time was 428 days [95% confidence interval (CI) = 212–680 days] in the RT arm versus 554 days (95% CI = 331 to not estimable) in the CRT arm.
Conclusions: Due to the early termination of this study, the effectiveness of concurrent use of carboplatin remains unclear. We re-planned and started a study with an active quality control program which was developed by the JCOG Radiotherapy Committee.
Key Words: non-small cell lung cancer • elderly patients • carboplatin • chemoradiotherapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, and M. Aapro EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population Ann. Onc., August 28, 2009; (2009) mdp360v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ishikura Quality Assurance of Radiotherapy in Cancer Treatment: Toward Improvement of Patient Safety and Quality of Care Jpn. J. Clin. Oncol., November 1, 2008; 38(11): 723 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild Lung Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907. [Abstract] [Full Text] [PDF]
|
|